Johnson & Johnson will begin human trials for a coronavirus vaccine candidate by September at the latest to be approved by early 2021, a timeline that would be on the faster end of what officials have said is possible.

The New Jersey-based pharmaceutical giant announced Monday that researchers aim to speed up the development process, which can take five to 15 years under normal circumstances, and gain emergency-use approval by the Food and Drug Administration.